Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
Roy S. Herbst(Smilow Cancer Hospital), David S. Mendelson(American Society of Clinical Oncology), Avi Ashkenazi(Molecular Oncology (United States)), Peter J. O’Dwyer(University of Pennsylvania), Meredith A. Goldwasser(Memorial Sloan Kettering Cancer Center), Razelle Kurzrock(Medical College of Wisconsin), William Novotny(Virginia Oncology Associates), Michael S. Gordon(Pinnacle Oncology Hematology), Tanyifor M. Tohnya(The University of Texas MD Anderson Cancer Center), S. Gail Eckhardt(Bayer (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bert L. Lum(The University of Texas MD Anderson Cancer Center), Adrian M. Jubb(Allogene Therapeutics (United States))
Cited by 443
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k